Match Context and Document information |
These search terms are highlighted: dea verification
URL: | https://www.deadiversion.usdoj.gov/...S_Comments_-_Fina2.pdf |
Depth: | 2 clicks away from Home |
Size: | 253,685 bytes |
Modified: | 2023-05-10 15:13:51 |
Categories: | -None- |
Title: | Drug Enforcement Administration Diversion Control Division Guidance Document |
Description: | -None- |
Keywords: | -None- |
Meta data: | -None- |
Body: | Drug Enforcement Administration
Diversion Control Division
Guidance Document
Title: COVID-19 Flexibility Updates
Summary: The Drug Enforcement Administration (DEA) granted certain flexibilities during the
COVID-19 Public Health Emergency (PHE). DEA has determined that some of those
flexibilities should remain in place under the ongoing Opioid PHE, to help respond to the opioid
crisis after the COVID-19 PHE expires at the end of the day on May 11, 2023. This document
describes which flexibilities will automatically terminate at the end of the day on May 11, 2023,
and which flexibilities will remain in effect under the Opioid PHE. DEA also is withdrawing
three guidance documents that mention the COVID-19 PHE.
Activity: Continuing Application of Certain COVID-19 PHE Related Flexibilities during the
Opioid PHE
To Whom it Applies: DEA Registrants and Others Impacted by PHE Related Flexibilities to
DEA Regulations
The Department of Health and Human Services (HHS) has announced that, based on current
COVID-19 trends, the federal COVID-19 Public Health Emergency (PHE), declared under
Section 319 of the Public Health Service (PHS) Act on January 31, 2020, will expire at the end
of the day on May 11, 2023.
The former Secretary of HHS determined on Oct. 26, 2017, that a separate public health
emergency exists nationwide as a result of the consequences of the opioid crisis affecting our
nation. This Opioid PHE was most recently renewed effective April 1, 2023.
During the COVID-19 PHE, the Drug Enforcement Administration (DEA) responded to the
needs of registrants for increased flexibilities both by exercising its authority under 21 CFR
1307.03 to issue temporary exceptions to DEA regulations and by indicating the circumstances
in which DEA will exercise its discretion in enforcing certain statutory requirements. This
document summarizes the status of the flexibilities following the expiration of the COVID-19
PHE on May 11, 2023. This document does not describe the status of telemedicine prescribing
flexibilities such as the guidance's on state reciprocity (DEA-DC-018 EO-DEA067) and
medications for opioid use disorder prescribed by telephone (DEA-DC-022 EO-DEA068), which
DEA and the Substance Abuse and Mental Health Services Administration addressed in the
temporary rule titled "Temporary Extension of COVID-19 Telemedicine Flexibilities for
Prescription of Controlled Medications" which publish in the federal register on May 10, 2023,
Temporary Extension.
During the COVID-19 Public Health Emergency, DEA extended the following flexibilities
under the Administrator's enforcement discretion, authority to interpret DEA's
regulations, and authority granted under 21 CFR 1307.03. DEA is further extending these
flexibilities to respond to the Opioid Public Health Emergency. They will remain in effect
until the expiration of the Opioid PHE unless first modified or withdrawn by DEA.
. Off-Site Delivery Methods for NTPs (methadone). An announcement of DEA's exercise
of authority to allow NTPs to repeatedly deliver take-home doses of methadone to the
same off-site location without becoming registered at that location, subject to certain
limitations. DEA-DC-025 EO-DEA078
. NTP Exception for Home Delivery. An exception to 21 CFR 1301.74(h) to allow NTPs
to make a "doorstep" delivery of take-home medication to a patient in the event a patient
is quarantined due to coronavirus. The guidance allows NTP staff, law enforcement, or
National Guard to deliver take-home doses of methadone or buprenorphine to a patient in
these circumstances. DEA-DC-015 EO-DEA064
. Off-Site Delivery Methods for NTPs (buprenorphine). An announcement of DEA's
exercise of authority to permit NTPs to repeatedly deliver take-home doses of
buprenorphine to the same off-site location without obtaining a separate registration for
that location, subject to certain limitations. DEA-DC-030 EO-DEA087
. Administering Certain Controlled Substances in the Parking Lot of a Healthcare
Provider's DEA-Registered Location. A clarification that DEA considers it permissible
to provide medically supervised treatment using controlled substances in a provider
parking lot, so long as the parking lot is located immediately adjacent to the provider's
DEA-registered facility and in compliance with all other applicable federal, state, local
and tribal laws and regulations. DEA-DC-043 EO-DEA213
. DEA Form 222: Scanning and Fax/Email to Supplier. An exception to the requirements
set forth under 21 CFR 1305.13 to allow DEA registrants who order controlled
substances to fax or scan/email a DEA Form 222 instead of submitting the original to the
supplier by mail. Upon the expiration of the emergency, purchasers will be required to
send suppliers hard copies of the executed DEA Form 222 that were transmitted to the
supplier via email or fax during the PHE. DEA-DC-019 EO-DEA066
The following exceptions will expire on May 11, 2023, at which time they will automatically
be rescinded and removed from the DEA and DOJ Guidance Document Portal. If
registrants seek the continued flexibility of any of these expiring exceptions, DEA would
encourage registrants to apply for an exception under 21 CFR 1307.03 by filing a written
request stating the reasons for such exception. Requests may be emailed to odlp@dea.gov
or sent by mail to Drug Enforcement Administration, Attn: Policy Section, 8701
Morrissette Dr., Springfield, VA 22152.
. Narcotic Treatment Program (NTP) Exception to Signing Invoices at Delivery. An
exception to 21 CFR 1301.74(h) that normally requires a licensed practitioner or other
authorized individual to sign an invoice at the time of delivery of controlled substances to
an NTP. DEA-DC-027, issued April 11, 2020.
. Hospital/Clinic Registration (Campus) Exception. An exception to 21 CFR 1301.12(a) to
provide DEA-registered hospital/clinics with the flexibility to utilize satellite
hospital/clinic locations under their current registrations under certain conditions. In
addition, DEA granted distributors an exception to the requirements of 21 CFR
1305.13(c) and 1305.22(f) to allow them to ship controlled substances directly to these
satellite hospitals/clinics, even though they are non-registered locations. DEA-DC-028,
issued April 11, 2020.
. Distributors Questions and Answers. DEA granted an exception to 21 CFR 1305.13(c)
and 1305.22(f) to allow deliveries to safe zones' adjacent to the purchaser's registered
location, provided that the delivery is still made in a person-to-person manner, with an
agent or employee of the purchasing registrant taking possession of the delivery within
sight of the delivery driver. DEA also referenced other COVID-19 PHE guidance
documents. DEA further indicated that due diligence and site inspections via
teleconferencing may be acceptable alternatives during the COVID-19 PHE. DEA-DC-
032, issued April 10, 2020.
. 5% Rule: Practitioner Exception. An exception to 21 CFR 1307.11 allowing a registered
practitioner to distribute controlled substances beyond' five percent of the total number
of dosage units of controlled substances distributed and dispensed during the same
calendar year without being required to register as a distributor. DEA-DC-029, issued
April 13, 2020.
. 65% Bulk Manufacturing Exception. An exception to 21 CFR 1303.24(b) that normally
requires the inventory for individual manufacturers to remain at 65 percent of estimated
net disposals or less. DEA-DC-020, issued March 25, 2020.
. Emergency Schedule II Call in Exception. While practitioners must determine on a case-
by-case basis whether an emergency' exists under the requirements of 21 CFR 290.10,
this guidance granted an exception to the requirements set forth under 21 CFR
1306.11(d)(4) to allow practitioners fifteen (15) days to provide a follow-up paper
prescription to the pharmacy after issuing an emergency oral prescription. It also granted
an exception allowing the practitioner to send the follow-up written prescription to the
pharmacy via facsimile, or to send a photograph or scan of the written prescription to the
pharmacy. DEA-DC-21, issued March 27, 2020.
. Prescription Chart. This decision tree summarized policies for quick reference but has
become out of date due to its reference to the DATA-waiver requirements that were
repealed by Congress in December 2022. DEA-DC-23, issued March 31, 2020.
To avoid confusion, DEA also is withdrawing the following guidances that mention the
COVID-19 PHE.
. Prescription Refills. Guidance concerning the refill of prescriptions for controlled
substances during the COVID-19 PHE. DEA-DC-17, issued March 21, 2020.
. Mail Order Methadone. Guidance concerning the delivery of methadone to NTP patients
by mail, mentioning other flexibilities granted during the COVID-19 PHE. DEA-DC-24,
issued March 25, 2020.
. EPCS Hospitals & Remote ID Proofing. Guidance relating to remote identity proofing of
individual practitioners when issuing authentication credentials to eligible practitioners
engaged in electronic prescribing of controlled substances during the COVID-19 PHE.
DEA-DC-26, issued April 8, 2020.
The contents of this document do not have the force and effect of law and are not meant to bind
the public in any way. This document is intended only to provide clarity to the public regarding
existing requirements under the law or Department of Justice policies.
For further information regarding DEA's Diversion Control Division, please visit
www.DEAdiversion.usdoj.gov. If you have additional questions, please contact the Diversion
Control Division Policy Section by email at odlp@dea.gov or by phone at (571) 362-3260.
Sincerely,
Claire M. Brennan
Acting Deputy Assistant Administrator
Diversion Control Division
EO-DEA277, DEA-DC-072, May 10, 2023
CLAIRE
BRENNAN
Digitally signed by CLAIRE
BRENNAN
Date: 2023.05.10 15:09:45 -04'00'
|
|